Preoperative Combined Radiotherapy and Chemotherapy for Middle and Lower Rectal Cancer: Preliminary Results
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Adjuvant treatment for rectal cancer is still controversial. This study reports on overall survival and disease-free survival, toxicity, downstaging, and surgical morbidity in rectal cancer patients who received combined chemoradiation therapy followed by curative surgery.
Methods: Between 1993 and 1998, 51 patients (31 males and 20 females; median age, 60 years; range, 33–73 years) underwent chemoradiation therapy followed by radical surgery for middle and lower rectal adenocarcinoma. Criteria for giving preoperative radiotherapy (total 45 Gy in 25 fractions of 1.8 Gy/day for 5 weeks) and chemotherapy (5-fluorouracil 350 mg/m2/day and leucovorin 10 mg/m2/day, bolus on days 1–5 and 29–33) were an age younger than 75 years; an Eastern Cooperative Oncology Group performance status score of 0 to 2; and clinical preoperative stage II–III. Forty-three low anterior and eight abdominoperineal resections were performed. Median follow-up time was 29 (range, 3–63) months.
Results: Although grade 3 to 4 toxicity occurred in 14 cases (27.4%), all patients completed the planned adjuvant therapy. At pathology, a complete response was found in eight (15.7%) cases. Of the remaining 43 cases, 22 were stage I, 12 were stage II, and 9 were stage III. Five-year actuarial disease-free survival and overall survival rates were 86.4% and 85.5%, respectively. Whereas no local recurrences were found, 4 patients had distant metastases. Three patients died (1 of cancerrelated causes), 45 are alive and disease free, and 3 are alive with disease.
Conclusions: The combined preoperative chemoradiation approach used by us seems to improve the disease-free survival and overall survival of selected patients with rectal cancer. However, a longer follow-up time is required to confirm these preliminary results.
- P¨hlman L. Current controversies in cancer: is radiochemotherapy necessary in the treatment of rectal cancer? Eur J Cancer 1998;34:438–441.
- Gastrointestinal Tumor Study Group. Prolongation of the diseasefreeinterval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465–1472. CrossRef
- Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709–715. CrossRef
- AJCC American Joint Committee on Cancer. Colon and Rectum. In: Fleming DI, Cooper SJ, Henson ED, et al, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997:83–90.
- NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1440–1445.
- Thomas PRM, Lindblad AS, Stablein DM, et al. Toxicity associated with adjuvant postoperative therapy for adenocarcinoma of the rectum. Cancer 1986;57:1130–1134.
- Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short-term radiotherapy in operable rectal carcinoma: a prospective randomized trial. Cancer 1995;75:2269–2275.
- Stockholm Colorectal Cancer Study Group. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol 1996;3:423–430.
- Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–987.
- Minsky BD, Cohen AM, Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 1992;10:1218–1224.
- Dahlberg M, Glimelius B, Graf W, P¨hlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 1998;41:543–551.
- Ota DM. Preoperative radiotherapy for rectal cancer: benefits and controversies. Ann Surg Oncol 1995;3:419–420.
- Haghbin M, Sischy B, Hinson J. Combined modality therapy in poor prognostic rectal adenocarcinoma. Radiother Oncol 1988;13:75–81.
- Chan A, Wong A, Langevin J, Khoo R. Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma. Int J Radiat Oncol Biol Phys 1993;25:791–799.
- Minsky BD, Kemeny N, Cohen AM, et al. Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. Cancer 1991;67:2859–2866.
- Boulis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Cancer 1984;53:1811–1818.
- Grann A, Minsky BD, Cohen AM, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997;40:515–522.
- Chari RS, Tyler DS, Anscher MS, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778–787.
- Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998;40:1067–1075.
- Rich TA, Skibber JM, Ajani JA, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025–1029.
- Stryker SJ, Kiel KD, Rademaker A, Shaw JM, Ujiki GT, Poticha SM. Preoperative. “chemoradiation” for stages II and III rectal carcinoma. Arch Surg 1996;131:514–519.
- Habr-Gama A, de Souza PMSB, Ribeiro U Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41:1087–1096.
- Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeonrelated factors and outcome in rectal cancer. Ann Surg 1998;227:157–167. CrossRef
- Dixon AR, Maxwell WA, Thornton Holmes J. Carcinoma of the rectum: a 10-year experience. Br J Surg 1991;78:308–311.
- MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457–460. CrossRef
- Zaheer S, Pemberton JH, Farouk R, Dozois RR, Wolff BG, Ilstrup D. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998;227:800–811.
- Ahmad NR, Nagle D. Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997;84:1445–1448.
- Saclarides TJ. Endorectal ultrasound. Surg Clin North Am 1998;72:237–249.
- Meterissian S, Skibber J, Rich T, et al. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1994;1:111–116.
- Marsh RW, Chu NM, Vauthey JN, et al. Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 1996;78:217–225.
- Pucciarelli S, Toppan P, Friso ML, et al. Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection. Dis Colon Rectum 1999;42:1276–1284.
- Kessler H, Hermanek P, Wiebelt H. Operative mortality in carcinoma of the rectum: results of the German Multicentre Study. Int J Colorect Dis 1993;8:158–166.
- Karanjia ND, Corder AP, Holdsworth PJ, Heald RJ. Risk of peritonitis and fatal septicaemia and the need to defunction the low anastomosis. Br J Surg 1991;78:196–198.
- Preoperative Combined Radiotherapy and Chemotherapy for Middle and Lower Rectal Cancer: Preliminary Results
Annals of Surgical Oncology
Volume 7, Issue 1 , pp 38-44
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Rectal cancer
- Adjuvant treatment
- Industry Sectors
- Author Affiliations
- 1. Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Università di Padova, Azienda Ospedaliera di Padova, Padova, Italy
- 4. Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione di Clinica Chirurgica II, Policlinico, VI Piano, Via Giustiniani 2, 35100, Padova, Italy
- 2. Divisione di Radioterapia, Azienda Ospedaliera di Padova, Padova, Italy
- 3. Divisione di Oncologia Medica, Azienda Ospedaliera di Padova, Padova, Italy